非小细胞肺癌的全球市场 - 市场规模，占有率，成长分析:各治疗法(标靶治疗，免疫疗法)，产业预测(2023年～2030年)

Global Non-Small Cell Lung Cancer Market Size, Share, Growth Analysis, By Therapy(Targeted Therapy, Immunotherapy) - Industry Forecast 2023-2030

出版日期: 2023年04月12日 | 出版商:

SkyQuest | 英文 165 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球非小细胞肺癌的市场规模，2021年为236亿6,489万美金，在预测期间(2023年～2030年)预计以13.9％的年复合成长率成长，从2022年的269亿4,836万美元到2030年扩大到763亿3,472万美元。

肺癌，尤其是非小细胞肺癌，在全球成为癌症相关死亡的主要原因。非小细胞肺癌的盛行率和发病率增加，促进有效的诊断用具，治疗的选项，对支持疗法手段的需求。高龄化，抽烟，环境污染物质的暴露，生活方式要素等，推动非小细胞肺癌的负担增加。

本报告提供全球非小细胞肺癌市场相关调查，市场概要，亲市场分析，市场动态及预测，各市场区隔、地区的市场分析，企业简介等资讯。

市场概要
市场规模
市场动态
- 促进因素
- 机会
- 阻碍因素
- 课题
主要的市场考察
- 技术分析
- 价格分析
- 供应链分析
- 价值链分析
- 市场生态系统
- 知识产权分析
- 贸易分析
- Start-Ups分析
- 原料分析
- 革新矩阵
- 开发中产品的分析
- 宏观经济指标
- 主要的投资分析
- 主要的成功因素
- 竞争的程度

市场动态及预测

市场动态
- 促进因素
- 机会
- 阻碍因素
- 课题
法规情形
波特分析
- 竞争企业间的敌对关係
- 替代品的威胁
- 买方议价能力
- 新加入业者的威胁
- 供给企业谈判力
未来混乱相关Skyquest的特别考察
- 政治影响
- 经济影响
- 社会影响
- 技术性影响
- 环境的影响
- 法律上的影响

全球非小细胞肺癌市场:各治疗法

市场概要
标靶治疗
免疫疗法
化疗

全球非小细胞肺癌的市场规模:各地区

市场概要
北美
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
南美
- 巴西
- 其他南美国家
中东、非洲
- GCC各国
- 南非
- 其他中东、非洲

竞争情形

前五名公司的比较
主要企业的市场定位(2021年)
主要的市场参与企业采用的策略
主要成功策略
- 各开发
- 各企业
- 各年度
市场上最近的活动
主要企业的市场占有率(2021年)

主要企业简介

Roche
AstraZeneca
Merck & Co.
Bristol-Myers Squibb
Pfizer Inc.
Novartis AG
Eli Lilly and Company
Celgene Corporation
Boehringer Ingelheim
AbbVie Inc.
Astellas Pharma Inc.
Takeda Pharmaceutical Company Limited
Sanofi S.A.
GlaxoSmithKline
Johnson & Johnson
Amgen Inc.
Ipsen S.A.
Eisai Co., Ltd.
Taiho Oncology, Inc.
Gilead Sciences, Inc.

简介目录

Product Code: SQMIG25K2005

Global Non-Small Cell Lung Cancer Market size was valued at USD 23664.89 million in 2021 and is poised to grow from USD 26948.36 million in 2022 to USD 76334.72 million by 2030, growing at a CAGR of 13.9% in the forecast period (2023-2030).

The global non-small cell lung cancer (NSCLC) market refers to the pharmaceutical and biotechnology industry focused on the diagnosis, treatment, and management of non-small cell lung cancer, which is the most common type of lung cancer. NSCLC accounts for a significant portion of lung cancer cases globally and encompasses various subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. The NSCLC market involves the development of targeted therapies, immunotherapies, chemotherapy, and supportive care options to improve patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Small Cell Lung Cancer Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

The global non-small cell lung cancer market is segmented based on therapy, region. Based on therapy it is categorized into targeted therapy, chemotherapy, and immunotherapy. Based on region it is categorized into: North America, Europe, Asia-Pacific, South America, and MEA.

Driver

Lung cancer, particularly NSCLC, remains a leading cause of cancer-related deaths worldwide. The increasing prevalence and incidence of NSCLC drive the demand for effective diagnostic tools, treatment options, and supportive care measures. Aging populations, tobacco smoking, exposure to environmental pollutants, and lifestyle factors contribute to the rising burden of NSCLC. Precision medicine approaches, such as molecular profiling and genomic testing, have revolutionized the treatment landscape for NSCLC. Targeted therapies that specifically target genetic mutations and alterations in cancer cells have shown promising results in improving patient outcomes. The development of companion diagnostics and personalized treatment strategies fuels the growth of the NSCLC market.

Restraint

NSCLC tumors can develop resistance to targeted therapies and immunotherapies over time. Tumor heterogeneity, the presence of different subclones within a tumor, contributes to treatment resistance and poses challenges in achieving durable responses. Overcoming drug resistance and understanding tumor heterogeneity are ongoing research priorities in the NSCLC market.

Market Trends

The NSCLC market is witnessing a shift towards combination therapies that involve the use of multiple treatment modalities, such as targeted therapies, immunotherapies, and chemotherapy. Combining therapies with different mechanisms of action aims to enhance treatment efficacy, overcome resistance, and improve patient outcomes. Liquid biopsies, which involve the analysis of circulating tumor DNA (ctDNA) and other biomarkers in blood samples, are gaining importance in the diagnosis and monitoring of NSCLC. These non-invasive tests offer the potential for real-time monitoring of tumor mutations and treatment response. Companion diagnostics that identify predictive biomarkers for targeted therapies and immunotherapies continue to play a crucial role in treatment decision-making. The NSCLC market is increasingly focused on patient-centric care, emphasizing the holistic management of patients' physical, emotional